Cutaneous manifestations following COVID‐19 vaccination: A report of 25 cases

Dermatologic Therapy, Journal Year: 2022, Volume and Issue: 35(8)

Published: June 18, 2022

Various adverse effects particularly cutaneous manifestations associated with different COVID-19 vaccines have been observed in practice. The aim of our study was to evaluate all patients who presented tertiary center skin following injection from September December 2021. All manifestation within 30 days or less vaccination were enrolled case-series. cases included diagnosed based on clinical and/or histopathological evaluation and other possible differential diagnoses ruled out. Twenty-five individuals including 16 (64%) males 9 (36%) females the mean age 47 ± 17.62 years (range 18-91) study. Twenty-two (88%) developed lesions after Sinopharm vaccine 3 (12%) manifested AstraZeneca vaccine. Six (24%) new-onset lichen planus (LP) 1 (4%) patient LP flare-up. Two (8%) psoriasis case showed exacerbation. One pemphigus vulgaris (PV) experienced a flare PV lesions. pityriasis lichenoides et varioliformis acuta (PLEVA) Other as follows: toxic epidermal necrolysis (TEN) (n = 1, 4%), bullous pemphigoid (BP) 2, 8%), alopecia areata (AA) pytriasis rosea herpes zoster small vessel vasculitis erythema multiform (EM) urticaria 3, 12%), morphea 4%). Physicians should be aware side especially vaccines.

Language: Английский

---

Plaque Psoriasis Exacerbation and COVID-19 Vaccination: Assessing the Characteristics of the Flare and the Exposome Parameters

Vaccines, Journal Year: 2024, Volume and Issue: 12(2), P. 178 - 178

Published: Feb. 9, 2024

The diverse patient population and widespread vaccination in the COVD-19 era make vaccine-triggered episodes of psoriasis an ideal model exposome research. This scenario explores fine balance between protective exacerbating factors, providing insights into complex relationship environmental exposure immunopathogenesis when a trigger appears, such as that hyperinflammatory state induced by COVID-19 vaccine. Analyzing interactions vaccine-induced phenomena parameters may provide clinically relevant information important for personalized medicine decision-making. We performed literature review seeking patients with plaque flares or new onset change another subtype, pustular erythrodermic flare, focusing on inner external traits patients. identified 71 flares, 12 new-onset psoriasis, 17 subtype change, assessed terms clinical presentation, post-vaccination flare period treatment status, well (genomics, oxidative stress, hormonal impact due to gender, aging, skin color) (UV, infectomics). Novel data following are primarily obtained combining episode features characteristics comparing them similar unrelated vaccination.

Language: Английский

---

Cutaneous vasculitis and vasculopathy in the era of COVID-19 pandemic

Frontiers in Medicine, Journal Year: 2022, Volume and Issue: 9

Published: Aug. 23, 2022

Cutaneous vasculitides encompass a heterogeneous group of clinicopathological entities, which may occur as single-organ vasculitis the skin or present skin-limited variant systemic (i.e., ANCA-associated vasculitis), and are triggered by various factors, including infections, drugs vaccines. The COVID-19 pandemic has challenged us with variety both disease- vaccine-associated manifestations, vasculitis. Among latter, cutaneous small-vessel vasculitis, previously known leukocytoclastic seems to be most reported in either scenario, i.e., natural infection vaccination. Vasculopathy without true vasculitic changes on histology develops but minority cases, mostly severe/critical patients, appears result endothelial injury due pauci-immune thromboembolic mechanisms. Herein, we provide an overview available literature COVID-19-associated anti-SARS-CoV-2-vaccine-associated Although evidence is limited isolated reports, proportion cases lacking histopathological confirmation, ample overlap pre-pandemic forms shown.

Language: Английский

---

Lichen planus after COVID-19 infection and vaccination

Archives of Dermatological Research, Journal Year: 2022, Volume and Issue: 315(2), P. 139 - 146

Published: Dec. 5, 2022

Language: Английский

---

Cutaneous small vessel vasculitis in the COVID-19 era: a systematic review

Skin Health and Disease, Journal Year: 2025, Volume and Issue: unknown

Published: April 22, 2025

Abstract Background Dermatological adverse effects may occur after COVID-19 infection or vaccine administration. Since the beginning of pandemic, several case reports and systematic reviews have been published on vasculitis associated with both vaccination. Fever, malaise, urticaria, rash are common symptoms COVID-19. These can also as reactions to vaccines. However, occurrence serious autoimmune due its is rare. Cutaneous small vessel (CSVV) an disorder that manifests palpable purpura petechiae involving extremities. It results from neutrophilic inflammation within around dermal vessels usually self-limited. Objective We provide a thorough review CSVV occurring in era. Methods followed PRISMA 2020 checklist for review, searching PubMed, Google Scholar, Cochrane, Embase. included reports, series, correspondence articles, letters editor written English. Characteristics each were then summarized analyzed. Results 39 cases our – 27 12 infection. Mean age onset was similar, but mean time sooner vaccination group. Common treatments systemic steroids, almost all patients experienced complete recovery exception few cohort. Conclusion While most self-limiting resolve no long-term sequalae, more severe appears be rather than

Language: Английский

---

Cutaneous Reactions Following COVID-19 Vaccination: A Review of the Current Literature

Clinical Cosmetic and Investigational Dermatology, Journal Year: 2022, Volume and Issue: Volume 15, P. 2369 - 2382

Published: Nov. 1, 2022

Abstract: The outbreak of coronavirus disease 2019 (COVID-19) represented a new worldwide challenge, strongly impacting on the global economy, overall health and lifestyle. Since then, several strategies have been adopted to contain widespread infection. Among these, vaccination is currently most important measure fight against pandemic. However, concerns such as slower-than-hoped-for rollout, hurried approval with limited data, mechanism action (in particular mRNA-based), uncertain duration protection they afforded were initially raised. Moreover, even if cutaneous reactions rarely reported in clinical trials, mass showed dermatologic not recognized, leaving dermatologists decide how diagnose treat them. In this scenario, should be ready promptly recognize these manifestations. Thus, aim manuscript review current literature following COVID-19 vaccination, particularly inflammatory dermatological diseases, order help clinicians better understand conditions provide an extensive overview all vaccine-related skin Keywords: reactions, vaccinations, side effects

Language: Английский

---

New-onset or flare-up of bullous pemphigoid associated with COVID-19 vaccines: a systematic review of case report and case series studies

Frontiers in Medicine, Journal Year: 2024, Volume and Issue: 11

Published: April 8, 2024

Numerous cutaneous manifestations have been associated with the Coronavirus Disease 2019 (COVID-19) outbreak and vaccination, but new-onset bullous pemphigoid (BP) or flaring up of pre-existing BP is a rare side effect COVID-19 vaccines that has mentioned to lesser extent in literature. Therefore, we aimed conduct systematic review focused on association between new- onset flare-up vaccination.

Language: Английский

---

Alopecia areata following COVID-19 vaccine: a systematic review

European journal of medical research, Journal Year: 2024, Volume and Issue: 29(1)

Published: July 5, 2024

Abstract Background To date, multiple cases of adverse reactions to COVID-19 vaccines have been reported worldwide. Alopecia areata (AA) is an uncommon type reaction in some articles and has a significant social psychological impact on patients. Our study aimed review the AA vaccine literature. Methods This systematic was conducted by searching for following international databases such as Embase, MEDLINE, PubMed, Web Knowledge, Ovid from December 2019 30, 2023. We included studies that provided data patients vaccination with at least one dose. Data sex, age, country/region origin, type, days between symptom presentation, manifestations AA, trichoscopy histopathological findings, treatment, outcomes were included. Results In total, 579 explored identified assessed, 25 total 51 review. Twenty-seven (52.9%) developed new-onset receiving vaccine, recurrence or exacerbation occurred after 24 (47.1%) preexisting disease. Five cause all cases. The Pfizer (45.1%) most frequently reported, followed ChAdOx1 nCoV-19 (27.5%), Moderna mRNA-1273 (19.6%), Sinopharm (3.9%) SinoVac (3.9%). within month 1st dose, then, incidence decreased gradually time. Topical systemic corticosteroids used 38 Eleven treated Janus Kinase inhibitor (jakinib) inhibitor, eight tofacitinib, three unspecified jakinib. However, 3 11 experienced exacerbations treatment. Conclusion rare, physicians should be aware this phenomenon improve early diagnosis appropriate

Language: Английский

---

Autoimmune bullous diseases during COVID-19 pandemic: 2022 update on rituximab and vaccine

Frontiers in Medicine, Journal Year: 2023, Volume and Issue: 10

Published: Jan. 19, 2023

Autoimmune bullous diseases (AIBDs) are a heterogeneous group of life-threatening disorders associated with subepidermal or intraepidermal blistering. Skin barrier alterations and prolonged immunosuppressive treatments increase the risk infections in patients AIBDs, who considered fragile. COVID-19 pandemic had heavy impact on these patients. Although advances have been made terms prevention treatment COVID-19, this topic remains significant as its waves could last several years and, so far, relevant proportion population worldwide is not vaccinated. This review 2022 update that summarizes discusses pandemic's burden AIBD mainly considering studies of: (i) sample dimension; (ii) quality control populations; (iii) possible standardization by age, gender country. The findings show that: infection severe course were comparable general population, except for rituximab-treated presented higher disease; mortality rate COVID-19-infected pemphigoid was than 121 cases onset 185 relapse exacerbation occurred after vaccination causal relationship has demonstrated far. Altogether, acquired knowledge also be important possible, albeit undesirable, future scenarios.

Language: Английский

---

Cutaneous vasculitis: Lessons from COVID-19 and COVID-19 vaccination

Frontiers in Medicine, Journal Year: 2022, Volume and Issue: 9

Published: Dec. 9, 2022

Cutaneous vasculitis (CV) is an inflammatory skin-limited vascular disease affecting the dermal and/or hypodermal vessel wall. From pathogenetic point of view, idiopathic forms are described as well induction from various triggers, such drugs, infections, and vaccines. Following SARS-CoV-2 pandemic outbreak, cases CV induced by both COVID-19 vaccinations have been reported in literature. The aim our work was to collect multiple available literature analyze frequency different vasculitis, their histological immunopathological features. Although rare, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) vaccines may provide interesting insights into pathogenesis these processes that future be useful understand mechanisms underlying cutaneous systemic vasculitis.

Language: Английский

---